Analysis on Clinical Outcomes of Low-Molecular Weight Heparin Combined with Magnesium Sulfate in Patients with Pre-Eclampsia

Ningning Wang¹, Chun Feng², Minghe Sun³, *Ying Pu⁴

1. Department of Obstetrics, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250013, China
2. Leijing Community, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250013, China
3. Department of Obstetrics, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou 215028, China
4. Functional Examination Section, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250013, China

*Corresponding Author: Email: pyhu7k@163.com

(Received 09 Jul 2021; accepted 05 Oct 2021)

Abstract

Background: We aimed to investigate the clinical effect of low molecular weight heparin (LMWH) combined with magnesium sulfate in patients with severe pre-eclampsia (PE).

Methods: A total of 70 patients with severe PE admitted in Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, China from Jun 2020 to May 2021 were enrolled and randomized into observation and control groups. The control group was treated with magnesium sulfate only, and the observation group was treated with small-dose LMWH combined with magnesium sulfate. The clinical effects and artery blood flow index were analyzed.

Results: The observation group had higher coagulation function than that in the control group. RI, S/D, and PI in the observation group after treatment were lower than those in the control group, with statistically significant differences (P <0.05). In serum and placental tissues, both kininase expression and TGF-1 levels of the observation group were higher than those of the control group, with lower PAPP-A, VCAM-1 and E-selectin levels than those in the control group.

Conclusion: Small-dose LMWH combined with magnesium sulfate can promote the expression of endogenous kallikrein, weaken the infiltration of cytotrophoblast, and improve the maternal blood clotting state in patients with severe PE. It also improves placental microblood flow and effectively prolong pregnancy, promotes fetal growth, and improves the clinical effects.

Keywords: Pre-eclampsia; Low molecular weight heparin; Magnesium sulfate; Coagulation function; Clinical effect

Introduction

Pre-eclampsia (PE) is one of the multiorgan damaging diseases characterized by hypertension (systolic pressure ≥ 160 mmHg or diastolic pressure ≥ 110 mmHg) and proteinuria ≥ 0.3g/24h
after 20 weeks of pregnancy, which can endanger the mother's life in severe cases, and its pathogenesis has not been clarified (1,2). According to statistics, up to 10% of pregnancies are affected by hypertension diseases such as PE (3-6). Correlation studies showed that the main pathogenesis of PE is insufficient uterine spiral artery recast, placental dysfunction, overactivation of inflammation and damaged vascular endothelial cells. The central links of the basic pathophysiological changes include spasm of small blood vessels and damage of vascular endothelial cells (7-11). Injury to the blood pressure endothelium due to neutrophil activation and adhesion to vascular endothelial cells to stimulate an inflammatory response is the major pathophysiological change of PE (12, 13). Signaling pathways, such as Mitogen-activated protein kinase (MAPK) and downstream target protein kinase (ERK1/2, and JNK) participate in the regulation of neutrophils activation process (14).

Low molecular weight heparin (LMWH) has functions of anticoagulation, anti-inflammatory, protecting vascular endothelial cells, reducing blood viscosity, regulating cell proliferation, and improving placental microcirculation (15). Application of LMWH in patients with early PE can reduce the recurrence rate of PE and improve the adverse outcome of mother and baby in pregnancy (16,17). LMWH plays a role in anticoagulation and anti-thrombus, promoting the proliferation of trophoblast cells, and regulating immunity in early PE. And it has certain positive significance to improving the prognosis of mothers with PE and their babies with high safety in its application.

For patients with severe PE who must undergo active intervention and early termination of pregnancy, magnesium sulfate is the preferred drug to prevent severe PE, with the functions of spasmolysis and controlling eclamptic convulsions. However, the effective blood magnesium concentration for the treatment is very narrow, and it will lead to respiratory, liver and kidney function damage and even sudden death when it is too high. Therefore, magnesium sulfate cannot be used for a long time with large amount (18).

To sum up, the early treatment of severe PE was mainly spasmolysis and antihypertensive, which, however, cannot improve the hypercoagulation state of blood (19-21). Although the development of the disease can be controlled, simple magnesium cannot achieve the expected effects, which is easy to increase a series of complications. As the increasing application in clinical treatment, LMWH combined with magnesium sulfate can effectively relieve small blood vessel spasms and improve the prognosis of newborns. Therefore, in this study, patients with severe PE were treated with LMWH combined with magnesium sulfate.

**Materials and Methods**

**Subjects**

A total of 70 patients with severe PE admitted to Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, China from Jun 2020 to May 2021 were enrolled. All pregnant women had regular menstrual cycle and clear final menstruation, without primary hypertension, liver and kidney diseases, cardiovascular and cerebrovascular diseases, and history of smoking and drinking. None of them had received spasmolysis and antihypertensive treatment before admission.

This study has been approved by the Ethics Committee of Suzhou Kowloon Hospital. Informed consent has been signed and obtained from all patients.

**Inclusion criteria**

1) All patients met the diagnostic criteria for severe PE: blood pressure ≥ 160 / 110 mmHg; urine protein ≥ 300 mg/24 h or random urinary protein (+); platelets < 100 * 10⁹/ L; Serum ALT or AST (+); and may be accompanied by upper abdominal discomfort, headache and other symptoms;
2) All patients have blurred vision, headache, coma, etc.;
3) The medical records were clear and complete;
4) Single fetus

Available at: [http://ijph.tums.ac.ir](http://ijph.tums.ac.ir)
5) All patients have knowingly signed informed consent forms.

**Exclusion criteria**
1) Patients who were allergic to or allergic to heparin;
2) Patients with multicoagulation dysfunction, multiple organ dysfunction and so on;
3) Patients with severe heart, liver failure and kidney failure;
4) Patients with fetal chromosomal abnormalities or fetal abnormalities.

**Treatment method**
Routine treatment was given to patients of two groups. The control group was treated with magnesium sulfate as follows: 20 mL of 25% magnesium sulfate was added to 100 mL of 5% glucose for intravenous infusion, controlling infusion rate at 30 drops/min, which was completed within 30 min, with the total daily dosage of magnesium sulfate not more than 30 g. After that, 60 mL of 25% magnesium sulfate was dissolved in 1000 mL of 25% glucose solution for intravenous infusion, with the infusion rate at 2 g/h, the daily dosage of 20 g, 1 time/d, and 5 days were taken as 1 course, which was continued to the end of patient delivery. After venous magnesium sulfate for 48 h, the maternal heart rate, systolic pressure, diastolic pressure and mean arterial pressure were recorded, and the patient was observed for vital signs, and terminated the pregnancy immediately if necessary.

The observation group was treated with a small dose of LMWH for 1 time/d, with subcutaneous injection. When taking medication, the patient's heart rate, breathing frequency, urine volume, knee reflex and other vital signs were closely observed, and the subject's conditions were evaluated again, 1 time/3 days. The drug was stopped at the end of pregnancy, with 5 days as 1 course.

**Uterine artery examination**
We adopted color Doppler ultrasonic diagnostic instrument, with the probe frequency of 2.5-5 MHz, transmission power less than 10 mW/cm. Uterine artery S/D (maximum blood flow velocity), RI (resistance index), and PI (pulsation index) were measured. The examination include moderate filling bladder, calm breathing, supine position, routine inspection of fetal double parietal diameter, head circumference and femur, humerus length, inspection of amniotic fluid, placenta, judge fetal intrauterine development. Uterine artery examination: The lower uterine muscle wall was found by avoiding intestinal gas interference on both sides of the cervical uterine junction. The intergateral artery was shown between the pelvic wall and the lower uterine muscle layer, and the uterine artery blood flow signal was found near the cervical opening. Sampling volume was placed on the upper branch of the uterine artery at the lateral edge of the muscle-wall, to obtain the continuous, stable and clutter free images of the uterine artery blood flow spectrum.

**Umbilical artery examination**
The umbilical artery of the near placenta was relatively stable. The umbilical artery was measured when the fetus was relatively quiet. The included Angle between the pulse Doppler sampling line and the umbilical artery was 60 °. The PI, RI and S/D of the fetal umbilical artery were measured after taking the blood flow spectrum of more than 5 consecutive cardiac cycles.

**Specimen collection and treatment**
After receiving different treatments, 5 mL of peripheral fasting venous blood of the patients was retained, naturally coagulated for 30 min and centrifuged at 4000 RPM for 10 min. The serum was separated and frozen for storage.

The placenta was delivered by cesarean section in both groups. The median tissues of maternal placenta was collected in the size of 2 cm × 2 cm × 2 cm, rinsed and removed the blood, and then placed in the -80 °C refrigerator for storage.

**Expression of kallikrein gene**
High-purity RNA was extracted from blood and placenta specimen, and cDNA was synthesized by reverse transcription polymerase chain reac-
tion method, with actin β as the internal parameter, kallikrein plasmid as the external parameter, 5'-CACAGCCAGTTTGTTCAT-3' as forward primer, and 5'-GGAAGGTGGCAAGACAC-3' as reverse primer. Cycle parameters: Pre-degeneration at 94 °C for 5 min, denatosis at 94 °C for 50 s, 56 °C annealing 1 min, 72 °C extends 50 s, for a total of 35 cycles, and finally 72 °C extends from 10 min to 4 °C to complete the reaction. The products of polymerase chain reaction and plasmid amplification were observed by agarose gel electrophoresis.

The levels of PAPP-A, SPI, PLGF, and HPL in serum and placental fluid were determined by enzyme linked immunosorbent assay (ELISA). Placental tissue was washed twice with 400 mL of TrisHcl (the inhibitor containing amino acid proteases) and centrifuged at 4 °C for 20 min, and then the supernatant was taken. The coagulation functions, including prothrombin time (PT), activated partial thrombin time (APTT), thrombin time (TT) and fibrinogen (FIB), were detected with the automatic biochemical analyzer.

**Statistical methods**

The data of detection indexes of the two groups were expressed by x±s, and processed with SPSS 22.0 (IBM Corp., Armonk, NY, USA) statistical analysis software. The differences between different groups were compared with variance analysis or chi-square test, and the data in the same group was tested with t test. P<0.05 represents statistically significant difference.

**Results**

**Comparison of general data**

Seventy patients with severe PE were enrolled, 35 of them were grouped into the control group, aged 22~36 yr old, with the average age of (26.47 ± 1.92) yr old, pregnant for 26~38 weeks, with the average gestational age of (35.63 ± 2.21) weeks. Another 35 patients were grouped into the observation group, pregnant for 26~39 weeks, with the average gestational age of (36.72 ± 1.97) weeks. All enrolled patients have completed the trials. The differences in age, gestational age and other general data were compared between the observation group and the control group, without statistical significance, which were comparable (Table 1).

| Group         | Age (yr)    | BMI (kg)   | Gestational age (week) |
|---------------|-------------|------------|------------------------|
| Control group | 29.36±3.76  | 65.87±7.05 | 35.80±3.18             |
| Observation   | 28.34±4.10  | 63.73±6.34 | 36.10±2.53             |
| Pregnant times| 1.94±0.91   | 2.08±0.89  | 0.973                  |
| t             | 1.078       | 0.360      | 0.667                  |
| P             | 0.620       | 0.521      | 0.973                  |

Table 1: Comparison of general clinical data between observation and control groups (n=35)
Comparative analysis of 24 h urinary protein quantification, systolic pressure and diastolic pressure

Before treatment, 24 h urinary protein quantification, systolic pressure and diastolic pressure were compared, without statistical significance. After treatment, 24 h urinary protein quantification, systolic pressure and diastolic pressure in the observation group were significantly better than those in the control group, and the differences were statistically significant (P <0.05), as shown in Table 2. The 24 h urinary protein quantification, systolic pressure and diastolic pressure of patients treated with LMWH combined with magnesium sulfate was better than those treated with magnesium sulfate, which may be related to the anti-inflammatory effects of LMWH combined with magnesium sulfate, indicating that LMWH combined with magnesium sulfate can effectively reduce vascular tension and inhibit neuromuscle activity.

Table 2: Comparative analysis of 24 h urinary protein quantification, systolic pressure and diastolic pressure in both groups ( x±s)

| Time            | Group                        | 24 h urinary protein quantification | Systolic Pressure | Diastolic Pressure |
|-----------------|------------------------------|------------------------------------|------------------|-------------------|
| Before treatment| Control group (n=35)         | 9.97±3.01                          | 160.15±10.32     | 97.23±6.42        |
|                 | Observation group (n=35)     | 10.32±2.97                         | 160.23±10.25     | 97.01±6.37        |
|                 | t                            | 0.695                              | 1.138            | 0.493             |
|                 | P                            | 0.254                              | 0.656            | 0.122             |
| After treatment | Control group (n=35)         | 7.92±2.04                          | 127.95±8.34      | 93.25±5.26        |
|                 | Observation group (n=35)     | 6.01±1.35                          | 119.64±7.93      | 87.34±5.11        |
|                 | t                            | 7.956                              | 3.628            | 4.223             |
|                 | P                            | 0.001                              | 0.029            | 0.015             |

Changes in uterine artery blood flow

Before treatment, uterine artery S/D of the observation group was 2.56 ± 0.31, and that of the control group was 2.49 ± 0.29, without statistical significance. After treatment, the uterine artery S/D in patients with severe PE of the observation group was lower compared with that in the control group, indicating a better treatment effect. Before treatment, RI was 0.63 ± 0.03 and 0.59 ± 0.04 in the patients of the observation group and the control group, respectively, without statistical significance. After treatment, RI significantly decreased in the observation group. And before treatment, uterine artery PI in patients with severe PE of the observation group was 1.53 ± 0.09, which was significantly lower compared with that before treatment, as shown in Fig. 1.
Changes in umbilical artery blood flow
Before treatment, there were no statistically significant difference in S/D, RI, and PI of umbilical artery, which were also not statistically significant after treatment, as shown in Fig. 2.

Umbilical artery blood flow S/D reflects placental microcirculation impedance and irrigation flow of placental blood flow, which can increase blood coagulation in pregnant women with severe PE, resulting in increased placental blood vessel resistance, decreased fetal placental blood circulation, increased S/D, leading to intrauterine hypoxia and limited growth. All the RI, PI and S/D values after treatment were significantly lower than those before treatment in the observation group, while there was no significant difference in RI, PI and S/D values before and after treatment in the control group. The combined treatment could effectively improve placental microcirculation in patients and help to correct the fetal growth restriction.

Expression of kallikrein
Before treatment, the kininase level in the blood of the control group and the observation group were 0.85±0.12, 0.83±0.08, respectively, without statistically significant difference. However, after treatment, kininase expression in serum of the observation group (1.47±0.21) was higher than that of the control group (0.87±0.09), with statistically significant difference (P<0.05).

Levels of PAPP-A, SPI, PLGF, and HPL
Levels of PAPP-A, SPI, PLGF and HPL in patients of the two groups were tested with rank-sum test. The level of PAPP-A in serum and placenta tissue of the observation group after treatment was (1.21±0.42), which was lower than those in the control group (2.03 ± 0.67), with statistically significance (P=0.006). After treatment, the levels of PLGF and HPL in serum and placental tissue of the observation group were also lower than those of the control group, with no statistical significance between the two groups. After treatment, the level of SPI in serum and placental tissue of the observation group was (0.92±0.09), which was higher than that of the control group (0.83±0.07), with no statistical significance between the two groups (Table 3 and Table 4).

### Table 3: Comparison of levels of PAPP-A, SPI, PLGF, and HPL in the two groups ( ±s)

| Group          | PAPP-A (mIU/mL) | SPI (μg/mL) | PLGF (pg/mL) | HPL (μg/mL) |
|----------------|-----------------|-------------|---------------|-------------|
| Control group  | 2.03±0.67       | 0.83±0.07   | 334.95±45.87  | 15.93±1.73  |
| (n=35)         |                 |             |               |             |
| Observation group | 1.21±0.42    | 0.92±0.09   | 326.14±45.42  | 15.40±1.72  |
| (n=35)         |                 |             |               |             |
| t              | 5.194           | 0.887       | 1.150         | 1.053       |
| P              | 0.006           | 0.221       | 0.995         | 0.626       |
Table 4: Comparison of levels of PAPP-A, SPI, PLGF, and HPL in the two groups (±s)

| Group                     | PAPP-A (mIU/mL) | SPI (µg/mL) | PLGF (pg/mL) | HPL (µg/mL) |
|---------------------------|-----------------|-------------|--------------|-------------|
| Control group (n=35)      | 1.91±0.63       | 0.85±0.05   | 371.16±45.86 | 15.84±1.69  |
| Observation group (n=35)  | 1.19±0.47       | 0.92±0.08   | 349.42±45.21 | 16.01±1.73  |

| t                        | 2.226           | 0.882       | 0.408        | 0.654       |
| P                        | 0.014           | 0.551       | 0.152        | 0.814       |

Levels of TGF-1, VCAM-1, and E selectin
Before treatment, the differences of TGF-β1, VCAM-1 and E selectin in serum and placental tissue were not statistically significant, which was comparable. After treatment, the levels of TGF-β1, VCAM-1 and E selectin in the serum in the control group were 179.45±23.14, 103.26±13.64 and 62.24±2.43, respectively, and those of the observation group were 257.37±40.12, 45.28±4.23 and 44.57±3.86, respectively. After treatment, the levels of TGF-β1 in serum and placental tissue of the observation group were higher than those of the control group, while the levels of VCAM-1 and E selectin were lower than those of the control group, with statistical significance (P<0.05).

Comparative analysis of the coagulation function indexes in the two groups
After treatment, the levels of PT, APTT, and TT of the two groups were higher than those before treatment, FIB level was lower than that before treatment. The levels of PT, APTT, and TT of the observation group were higher than that of control group, and FIB level was lower than that of the control group (P<0.05), as shown in Table 5. Four coagulation indexes are commonly used for clinical monitoring of blood coagulation status and anticoagulant dosage. In the observation group and control group before treatment, PT was shorter than normal level and FIB was lower than normal level, indicating that the coagulation mechanism was abnormal and the blood was in a state of hypercoagulation. After treatment, PT and FIB in the observation group were significantly increased and higher than those in the control group, while there was no significant change in the control group, indicating that low molecular weight heparin combined with magnesium sulfate can effectively improve the hemagglutination status of pregnant women.

Table 5: Comparison of coagulation function indexes between control and observation groups (±s)

| Time          | Group                     | PT (s)  | APTT (s) | TT (s)  | FIB (g/L) |
|---------------|---------------------------|---------|----------|---------|-----------|
| Before treatment | Control group (n=35)      | 8.60±0.79 | 27.31±2.04 | 11.48±1.42 | 5.28±0.54 |
|               | Observation group (n=35)  | 8.53±0.56 | 27.37±1.94 | 11.57±1.32 | 5.34±0.52 |
|               | P                        | 0.25    | 0.21     | 0.16    | 0.34      |
| After treatment | Control group (n=35)      | 11.97±1.06 | 30.97±1.02 | 13.36±1.04 | 3.26±0.21 |
|               | Observation group (n=35)  | 14.21±0.46 | 35.02±0.98 | 15.01±0.92 | 2.15±0.17 |
|               | P                        | 0.000   | 0.000    | 0.000   | 0.000     |
Discussion

Severe PE is a relatively common pregnancy disease in obstetrics and gynecology, with its incidence rate about 3.9%. In the past, relevant scholars took more immediate pregnancy termination methods in patients with severe PE, regardless of the number of weeks of pregnancy, resulting in an increased rate of iatrogenic preterm birth and perinatal mortality. In recent years, with the continuous development of intensive medicine, more and more obstetricians choose to adopt conservative treatment to extend the time of maternal pregnancy to improve neonatal survival while ensuring the safety of maternal life. In the past, simple magnesium sulfate was treated clinically to prolong the pregnancy of PE (22).

Although magnesium sulfate can prolong the gestational age and promote fetal development, the protective effect on the patient's liver and kidney function is not obvious, and it cannot improve the high coagulation state of blood (23). LMWH is a small molecular fragment product of ordinary heparin demosynthesis and reduces the inhibition of thrombin (24). LMWH combined with magnesium sulfate has many advantages compared with simple magnesium sulfate to quickly improve the clinical symptoms (25).

In this study, the observation group had significantly better efficiency than those in the control group, indicating that magnesium sulfate with LMWH can effectively improve clinical effects and improve the viability of the fetus. In this study, 24 h urinary protein quantification and diastolic pressure in patients treated with magnesium sulfate and LMWH were significantly better than those treated with simple magnesium sulfate, which may be related to spasmolysis, sedation and blood reduction in LMWH combined with magnesium sulfate, indicating that LMWH combined with magnesium sulfate can effectively improve the coagulation function of patients.

Conclusion

The use of LMWH combined with magnesium sulfate for severe PE, effectively control the disease, can effectively improve the pregnant blood hypercoagulation, reduce the systolic pressure, improve placental microcirculation, help to promote fetal growth, improve efficacy, and high safety, has clinical promotion and application value.

Journalism Ethics considerations

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

Acknowledgements

No funding was received in this study.

Conflict of interest

The authors declare that there is no conflict of interest.

References

1. Lamarca B (2010). The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia. Minerva Ginecol, 62(2): 105-120.
2. Cunningham FG, Leveno KJ, Bloom SL, et al (2010). Williams Obstetrics. 23rd ed. New York: McGraw-Hill Professional, 2010: 760-765.
3. Farrar D, Tuffnell D, Shelton TA (2020). An evaluation of the influence of the publication of the UK National Institute for health and Care Excellence's guidance on hypertension in pregnan-
cy: a retrospective analysis of clinical practice. 
BMC Pregnancy Childbirth, 20: 101.
4. Leblanc S, Ouellet A, Giguère Y, Forest JC, Moutquin JM, Aris A (2012). A positive correlation between hydrogen peroxide and soluble TNF-alpha receptor 2 early in maternal blood and at term in placenta of pregnant women with preeclampsia. Hypertens Pregnancy, 31(3): 357-366.
5. Frias AE Jr, Belfort MA (2003). Post Magpie: how should we be managing severe Preeclampsia? 
Curr Opin Obstet Gynecol, 15: 489-495.
6. Naljayan MV, Karumanchi SA (2013). New developments in the pathogenesis of preeclampsia. Adv Chronic Kidney Dis, 20(3): 265-270.
7. Zhang H, He Y, Wang JX, (2020). miR-30-Sp-mediated ferroptosis of trophoblasts is implicated in the pathogenesis of preeclampsia. Redox Biol, 29: 101402.
8. Duley L. (2009). The global impact of pre-eclampsia and eclampsia. Semin Perinatol, 33(3): 130-137.
9. Knöfler M, Haider S, Saleh I, Pollheimer J, Garnage TKJB, James J (2019). Human Placenta and Trophoblast development: Key Molecular Mechanisms and Model Systems. Cell Mol Life Sci, 76(18): 3479-3496.
10. Riddler A, Giorgione V, Khalil A, Thilaganathan B (2019). Preeclampsia: The Relationship between Uterine Artery Blood Flow and Trophoblast Function. Int J Mol Sci, 20(13): 3263.
11. Warrington JP, Coleman K, Skaggs C, et al (2014). Heme oxygenase-1 promotes migration and beta-epithelial Na+ channel expression in cytotrophoblasts and ischemic placentas. Am J Physiol Regul Integr Comp Physiol, 306(9):R641-646.
12. Sircar M, Thadhani R, Karumanchi SA (2015). Pathogenesis of preeclampsia. Curr Opin Nephrol Hypertens, 24(2): 131-138.
13. Mayrink J, Costa ML, Cecatti JG (2018). Preeclampsia in 2018: Revisiting Concepts, Physiopathology, and Prediction. Scientific World Journal, 2018: 6268276.
14. García-Hernández V, Samiento N, Sánchez-Bernal C, et al. (2016). Changes in the expression of LIMP-2 during cerulein-induced pancreatitis in rats: Effect of inhibition of leukocyte infiltration, cAMP and MAPKs early on in its development. Int J Biochem Cell Biol, 72: 109-117.
15. Mello G, Parretti E, Fatini C, et al (2005). Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension, 45(1): 86-91.
16. Mostello D, Catlin TK, Roman L, Holcomb WL Jr, Leet T (2002). Preeclampsia in the parous woman: who is at risk. Am J Obstet Gynecol, 187(2): 425-429.
17. Phipps E, Prassanna D, Brima W, Jim B (2016). Preeclampsia: Updates in Pathogenesis, Definitions, and Guidelines. Clin J Am Soc Nephrol, 11(6): 1102-1113.
18. Raghuraman N, March MI, Hacker MR, et al (2014). Adverse maternal and fetal outcomes and deaths related to preeclampsia and eclampsia in haiti. Pregnancy Hypertens, 4(4): 279-286.
19. Yifu P, Lei Y, Yujin G, Xingwang Z, Shaoming L (2020). Shortened postpartum magnesium sulfate treatment vs traditional 24h for severe preeclampsia: a systematic review and meta-analysis of randomized trials. Hypertens Pregnancy, 39(2): 186-195.
20. de Lima ASD, Holanda IP, Nascimento PRP, Jeronimo SMB, Ferreira LC (2021). Plasma angiotensin II levels in women with severe preeclampsia under magnesium sulfate regimen. Pregnancy Hypertens, 23: 56-58.
21. Wen J, Zhang X, Li C (2019). Clinical Effect of Low Molecular Weight Heparin Sodium Combined with Magnesium Sulfate in the Treatment of Patients with Severe Preeclampsia. J Cell Physicians Surg Pak, 29(2): 119-122.
22. Ueda A, Kondoh E, Kawasaki K, et al (2016). Magnesium sulphate can prolong pregnancy in patients with severe early-onset preeclampsia. J Matern Fetal Neonatal Med, 29(19): 3115-3120.
23. Burwick RM, Vélásquez JA, Valencia CM, et al (2018). Terminal Complement Activation in Preeclampsia. Obstet Gynecol, 132(2): 1477-1485.
24. Almaghamsi A, Almalki MH, Buhary BM (2018). Hypocalcemia in Pregnancy: A Clinical Review Update. Oman Med J, 33(6): 453-462.
25. Francis AP, Chang M, Dolin CD, Chervernak J, Cardonick E (2018). Recurrent Cholangiocarcinoma in Pregnancy: A Case Report. AJR Rep, 8(4): e261-e263.